The European Medicines Agency and the US Food and Drug Administration are looking at ways to exchange notes on drugs that become eligible for their respective schemes on speeding access to new innovative medicines, that is, Priority Medicines (PRIME) in the EU and breakthrough therapy designation in the US.
The exercise involves considering how to facilitate parallel discussion on medicines admitted under PRIME and those that receive breakthrough therapy designation to support the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?